Extreme T hrombocytosis in Response to PEG-ADA: Early Therapeutic and Risk Indicator

Abstract

Get full access to this article

View all access options for this article.

References

1. Buckley RH , Schiff RI , Schiff SE , et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387.

2. Giblett ER , Anderson EE , Cohen F , et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972; 2:1067-1069.

3. Polmar SH , Stern RC , Schwartz AL , et al. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med. 1976;295:1337-1343.

4. Hershfield MS , Buckley RH , Greenberg ML , et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl j Med. 1987;316: 589-596.

5. Gelfard EW , Dosch HM . Diagnosis and classification of severe combined immunodeficiency disease. Birth Defects. 1983;19:65-72.

6. Conley ME . X-linked severe combined immunodeficiency. Clin munol Immunopathol. 1991;61:S94-S99.

7. Hirschhorn R . Inherited enzyme deficiencies and immunodeficiency: adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiencies. Clin Immunol Immunopathol. 1986;40:157-165.

8. Hershfield MS . PEG-ADA replacement therapy for adenosine deaminase deficiency: an update for 8.5 years. Clin Immunol Immunopathol. 1995;76:S228-S232.

9. Hershfield MS , Chaffee S , Sorensen RU . Enzyme replacement therapy with polyethylene glycol-adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Pediatr Res. 1993;33:S42-S47.